See every side of every news story
Published loading...Updated

Acelyrin Sees Stock Price Rise Amid Rights Plan - Los Angeles Business Journal

Summary by labusinessjournal.com
Drug development company Acelyrin Inc. recently saw a modest increase in its stock price after announcing the adoption of a shareholder rights plan in connection with an unsolicited offer from Concentra Biosciences and Tang Capital Partners, its controlling shareholder. Acelyrin, based in Agoura Hills, saw an increase in share price of just above 2% from the closing price of $2.69 on March 13 to a close of $2.75 on March 14. The company announce…
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

labusinessjournal.com broke the news in on Monday, March 24, 2025.
Sources are mostly out of (0)

You have read out of your 5 free daily articles.

Join us as a member to unlock exclusive access to diverse content.